Cargando…
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
BACKGROUND: EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and release of tumour proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab and gefitinib in combination for TKI-naive patients with advanced EGFRm NSCLC was evaluated. METHODS: This Phase 1 o...
Autores principales: | Creelan, Benjamin C., Yeh, Tammie C., Kim, Sang-We, Nogami, Naoyuki, Kim, Dong-Wan, Chow, Laura Q. M., Kanda, Shintaro, Taylor, Rosemary, Tang, Weifeng, Tang, Mei, Angell, Helen K., Roudier, Martine P., Marotti, Marcelo, Gibbons, Don L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852511/ https://www.ncbi.nlm.nih.gov/pubmed/33012782 http://dx.doi.org/10.1038/s41416-020-01099-7 |
Ejemplares similares
-
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019) -
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023) -
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure
por: Mizuno, Takaaki, et al.
Publicado: (2020) -
EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010) -
Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2021)